Pádraig O'Sullivan
Question:2271. Deputy Pádraig O'Sullivan asked the Minister for Health the potential direct savings the HSE would have realised, had positive reimbursement recommendations been issued by the HSE for ravulizumab, for the treatment of paroxysmal nocturnal haemoglobinuria and atypical haemolytic uremic syndrome, in each year since 2022, in tabular form; and if he will make a statement on the matter. [32237/24]
View answer